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Abstract
Restenosis remains the main complication of balloon angioplasty and/or stent implantation. Preclinical testing of new
pharmacologic agents preventing restenosis largely rely on porcine models, where restenosis is assessed after endothelial
abrasion of the arterial wall or stent implantation. We combined endothelial cell denudation and implantation of stents to
develop a new clinically relevant porcine model of restenosis, and used this model to determine the effects of an a4 integrin
inhibitor, ELN 457946, on restenosis. Balloon-angioplasty endothelial cell denudation and subsequent implantation of bare
metal stents in the left anterior descending coronary, iliac, and left common carotid arteries was performed in domestic
pigs, treated with vehicle or ELN 457946, once weekly via subcutaneous injections, for four weeks. After 1 month,
histopathology and morphometric analyses of the arteries showed complete healing and robust, consistent restenotic
response in stented arteries. Treatment with ELN 457946 resulted in a reduction in the neointimal response, with decreases
in area percent stenosis between 12% in coronary arteries and 30% in peripheral vessels. This is the first description of a
successful pig model combining endothelial cell denudation and bare metal stent implantation. This new double injury
model may prove particularly useful to assess pharmacological effects of drug candidates on restenosis, in coronary and/or
peripheral arteries. Furthermore, the ELN 457946 a4 integrin inhibitor, administered subcutaneously, reduced inflammation
and restenosis in stented coronary and peripheral arteries in pigs, therefore representing a promising systemic therapeutic
approach in reducing restenosis in patients undergoing angioplasty and/or stent implantation.
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Introduction
Coronary artery disease (CAD) is the leading cause of death in
most developed countries. Percutaneous coronary intervention and
implantation of stents have revolutionized the treatment of CAD.
However, restenosis (narrowing of the vessel lumen) remains one
major complication of coronary angioplasty and stent placement [1].
In this context, drug-eluting stents (DES; e.g. sirolimus- or paclitaxel-
eluting stents)became the standard of care for the treatment of CAD,
due to their strikingly reduced rates of restenosis compared with bare-
metal stents [2,3]. However, safety concerns with DES recently arose
with reports of increased late in-stent thrombosis, possibly associated
with increased mortality and myocardial infarction [4]. These
findings have renewed interest for alternative or complementary
interventions to reduce restenosis, including systemic pharmacolog-
ical treatments after bare metal or drug-eluting stent placement.
Restenosis studies are performed to unravel the fundamentals of
arterial healing to injury, or to assess preclinical safety or efficacy of
novel devices or pharmacological treatments. They rely on a
number of animal models, in which an initial injury to the arterial
wall is applied [5–8], most frequently either by using angioplasty
balloons to induce endothelial cell denudation, or by implanting
stents. Cholesterol-raising diets have also been used to enhance
lesion formation [9,10]. Among these models, the pig is commonly
used, because porcine heart and vasculature, anatomy and
physiology, as well as pathophysiology of the neointimal response
after vessel injury, present numerous similarities to those in humans
[11].Pigmodels haveusuallydemonstratedgood predictivevalue in
subsequent clinical trials [4,5,8,11], although current data shows
better predictivity for safety than for efficacy assessments. For
efficacy studies, one critical requirement of an appropriate model is
consistent and sufficient neointimal hyperplasia, to subsequently
allowvalidassessmentoftheeffectsofthedrugordevice tested.This
is particularly true for peripheral arteries, which show high elasticity
and biomechanical compliance, and do not consistently exhibit
sufficient neointimal hyperplasia.
PLoS ONE | www.plosone.org 1 December 2010 | Volume 5 | Issue 12 | e14314In vivo studies show increasing evidence of the pivotal role of
inflammation in post-stenting restenosis [12]. The inflammatory
reaction resulting from arterial injury and accompanying the
wound healing process influences neointimal growth and lumen
narrowing [12,13]. Inflammatory cells including monocytes,
leukocytes, neutrophils and macrophages are recruited and
accumulate as infiltrates primarily on the site of arterial wall
injury [12]. In a rabbit arterial injury model, neutrophil
accumulation on the medial and neointimal layer of the injured
artery was reduced after administration of an anti-inflammatory
agent [14]. Vascular cell adhesion molecule-1 (VCAM-1) is
expressed on activated endothelium and mediates capture and
migration of circulating mononuclear cells expressing a4b1
integrin [15]. Blockade of the VCAM-1 and a4b1 integrin
(VLA-4) interaction was shown to decrease lymphocyte trafficking
from the periphery into the vessel wall, attenuate leukocyte
recruitment and neointimal formation [16]. In a rabbit carotid
arterial electrical injury model, a 70% decrease in infiltrating
neointimal mononuclear leukocytes was observed after adminis-
tration of an anti-a4 integrin antibody [17]. In ApoE deficient
mice, blocking the a4b1-VCAM-1 interaction using an antibody
against a4b1 integrin resulted in reduction of monocyte rolling
and adhesion after carotid air dessication injury [18], and in a
72% reduction in neointimal thickening [16]. In a porcine
coronary artery model of single balloon injury, a4 inhibition was
associated with significant decrease in neoadventitial formation (14
days post injury) and lumen narrowing (3 and 14 days after injury)
[19].
ELN 457946 is a novel compound developed by Elan
Pharmaceuticals, which inhibits the a4 integrin-mediated adhesion
of leukocytes to VCAM-1. ELN 457946 has strong binding affinity
to lymphocytes in vitro through a4 integrin, and subcutaneous
administration of ELN 457946 in vivo resulted in increased
lymphocytes counts in the blood (Dofiles and Gunther, Elan
Pharmaceuticals; unpublished data; 2007). ELN 457946 was
shown to resolve paralytic symptoms and to reverse histopatho-
logical changes of disease in animal models of multiple sclerosis
(Dofiles, Elan Pharmaceuticals; unpublished data; 2006). Here, we
use this compound to further explore the role of a4 integrin in
arterial remodeling and restenosis.
Here we developed a double injury model, combining
endothelial denudation with an angioplasty balloon and implan-
tation of bare metal stents in normal swine arteries. One month
after the interventional procedure, complete healing was observed
in all animals, and area percent in-stent stenosis was 64% in the
left anterior descending (LAD) coronary arteries, and approxi-
mately 15% and 30% in the iliac and carotid arteries, respectively.
Therefore, this double injury porcine model leads to robust and
consistent restenosis, even in highly elastic peripheral arteries, and
may provide an improved preclinical model to observe pharma-
cological effects of candidate drugs on neointimal response. Using
this model, we investigated the effects of ELN 457946, an a4
integrin inhibitor, on vascular healing and restenosis. We showed
that ELN 457946-treated animals exhibited reduced inflammation
in the stented vessels, as well as decreases in area percent in-stent
stenosis of 12% in the LAD and 30% in the iliac and carotid
arteries, compared to control animals.
Methods
Ethics statement
All animal care and procedures conformed with the Guide for
the Care and Use of Laboratory Animals published by the US
National Institutes of Health (NIH Publication No. 85-23, revised
1996) and were approved by Charles River Laboratories
Institutional Animal Care and Use Committee.
Animals, Treatments and Surgical procedure
Male Yorkshire pigs (Sus scrofa; 3 month; 28–32 kg; Animal
Biotech Industries, Danboro, Pennsylvania) were maintained on
standard pig chow. Animals were dosed subcutaneously with
vehicle (phosphate buffered saline [PBS]; n=6), or 30 mg/kg
ELN 457946 (n=7), once weekly for four weeks (Days -1, 7, 14,
and 21). Animals received aspirin (81 mg, PO) and clopidogrel
(75 mg, PO), starting 2 days before surgery and until necropsy;
and nifedipine (30 mg, PO), cefotaxime (50 mg/kg, IV) and
buprenorphine (0.01 mg/kg, IM), prior to surgery. Under
isoflurane anesthesia, and after heparin administration (50–
150 IU/kg, IV), an 8F arterial sheath (Medtronic) was inserted
in the right common carotid artery. Under fluoroscopic guidance,
a 6F guide catheter was advanced through the sheath to the LAD
ostium. Endothelial cell denudation was performed using an
angioplasty balloon catheter (NC Raptor PTCA, Cordis) advanced
to the proposed location, appropriately inflated, and moved back
and forth 5 times over approximately 1.0 cm. One stent
(MicroDriver or Driver, 2.75–3.5 mm 618 mm, Medtronic) was
placed in the LAD, to achieve a target balloon-to-artery ratio of
1.1–1.2:1. Endothelial injury (Sailor Plus, Admiral extreme PTCA
balloon catheter, ev3) and stent deployment (Aurora, self-
expandable nitinol stents, 6 mm 640 mm, Medtronic) were
similarly performed in one iliac and the left carotid artery.
Angiographic images (OEC 9800H Fluoroscope and Visipaque
TM,
GE Health Care) of the vessels were obtained on the day of
surgery and necropsy. Euthanasia (sodium pentobarbital, 60 mg/
kg IV and exsanguination) was performed on Day 30–31, in
accordance with accepted AVMA guidelines.
Clinical pathology and Pharmacokinetic analysis
Blood was collected from the precava in isoflurane-anesthetized
animals. Hematology parameters were obtained at predose,
48 hours after each dose, and prior to necropsy (Bayer ADVIA
120 hematology analyzer; Siemens Diagnostics, Ramsey, Minne-
sota). Statistical analysis was performed using a Mann-Whitney
test (significance at p,0.05). Plasma concentrations of ELN
457946 were determined, at predose and 0.5, 2, 4, 24, 36, and
48 hours after dose (first and fourth doses); at predose and
48 hours after dose (second and third doses); and prior to
necropsy, using a research bioanalytical HPLC-MS/MS method.
An internal standard was added and samples were prepared using
protein precipitation and liquid-liquid extraction. Following
chromatographic HPLC separation, ELN 457946 was quantified
using tandem mass spectrometry. Analysis was performed using an
API-3000 triple quadrupole mass spectrometer (Applied Biosys-
tems, Foster City, CA) with electrospray ionization (ESI) in the
positive ion mode. Pharmacokinetic analysis was conducted using
WinNonlin (V5.2).
Tissue processing, Histopathology and Quantitative
Morphometry
The heart, descending aorta and brachiocephalic trunk were
perfusion fixed with lactated Ringer’s solution and 10% neutral
buffered formalin. Stented vessels were dissected, embedded in
epon (Spurr), trimmed at three levels (proximal, middle and distal),
sectioned, and resulting slides were stained with hematoxylin and
eosin and elastin trichrome. Neointimal hyperplasia was quanti-
tatively assessed using histomorphometric measurements of the
internal and external elastic lamina (IEL and EEL, respectively)
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Neointima area, media area, percent stenosis, lumen diameter,
and neointima thickness values were derived from these
measurements. Statistical analysis was performed using MicrosoftH
Excel Student’s t-test (significance at p#0.05). Semiquantitative
analysis was performed using terminology and grading scales
consistent with published recommendations (HSRL, 20 Frederick
Road, Thurmont MD) to assess the biological response of vascular
tissue to the stents [20]. A grading score of 0, 1, 2 or 3,
corresponding to absent, slight or minimal, moderate, or marked
biological response, respectively, and based on the extent of the
circumference of the artery involved, was applied to each studied
parameter. Main microscopic parameters analyzed included
inflammation, neointima fibrin and fibrinoid deposits, neiontima
maturity (degree of organization and presence of smooth muscle
cells), media hypocellularity, adventitial fibrosis, endothelialization
scores, and vessel wall injury.
Results
Study Design and Surgery
A total of 13 male young adult Yorkshire pigs were dosed
subcutaneously with vehicle (6 animals) or 30 mg/kg ELN 457946
(7 animals), once weekly, for a total of 4 injections (Figure 1). This
dosing scheme was selected based on a previous pharmacokinetic
study using a single 10 mg/kg subcutaneous dose in swine. The
once weekly, 30 mg/kg dose of ELN 457946 was anticipated to
provide appropriate exposure and efficacy throughout the study.
The first dose was administered at least 24 hours prior to the
surgical procedures. Animals underwent a single surgical proce-
dure consisting of endothelial cell denudation by angioplasty
balloon injury and subsequent implantation of one stent in each
the left anterior descending coronary artery (LAD), a right or left
iliac artery (RIA or LIA), and the left common carotid artery
(LCCA), when possible. One month after surgery, the animals
were euthanized and the stented vessels and adjacent areas were
collected and prepared for histopathologic evaluation.
As a result of the surgical procedures, a total of 6 LAD, 6 iliac (5
RIA and 1 LIA), and 6 LCCA arterial stents were placed in 6
vehicle-treated animals, and a total of 6 LAD, 6 RIA, and 6 LCCA
stents were placed in 7 ELN 457946-treated animals. Quantitative
angiography confirmed that the desired stent:artery ratio of 1.1–
1.2:1 was achieved for all vessels in all animals, with the exception
of the distal portion of the iliac artery in one ELN 457946-treated
animal. Data from this vessel were excluded from all subsequent
analyses.
No early deaths were observed after stent implantation. There
were no abnormal clinical observations following treatment with
ELN 457946 or vehicle. Animals in both treatment groups gained
an average of 5.3–5.4 kg in body weight during the course of the
study, and clinically tolerated well the surgical procedures and
treatments.
Double injury model: Histology of stented vessels
Proximal and distal non-stented artery segments did not show
sufficient neointimal response (data not shown) and were not
evaluated further. Representative histology of stented vessels,
harvested at euthanasia, one month after stent placement, is shown
in Figure 2.
Procedural injury was nearly absent in the stented peripheral
arteries, as reflected by intact elastic lamina and near lack of mural
laceration (Figure 2A; average score of 0.0060.00 for carotid, and
0.0660.14 for iliac arteries), and was very minimal in the stented
LAD (average score of 0.5060.66). All individual vessels
demonstrated successful stent implantation with no or very limited
associated procedural injury, and were therefore suitable for
further histopathology and histomorphometry analyses. Endothe-
lialization of the neointima was complete in all stented LADs
(Figure 2B; average score of 3.0060.00), and most peripheral
arteries (average score of 2.9460.14 for carotid, and 2.7260.44
for iliac arteries), independently of treatment group. Occasional
incomplete endothelialization was observed for peripheral vessels,
at levels where stent struts were not covered by neointima, and
likely corresponded to procedural stent malapposition (under-
deployment; data not shown). Optimal healing, with formation of
a robust, stable full thickness mature neointima, with a well-
organized and dense population of smooth muscle cells (Figure 2C;
also see Figure 2A–D), was observed in all LAD (average score of
3.0060.00) and peripheral vessels (average score of 2.9460.14 for
carotid, and 2.5660.50 for iliac arteries). Occasional slightly
incomplete maturation was observed in a few peripheral arteries,
independently of treatment group (data not shown). Light
dispersed deposits of fibrin/fibrinoid were observed around or in
the area of the stent struts (Figure 2D and asterisks in Figure 2C,
E–F) in stented LADs and peripheral arteries, in amounts which
were consistent with the advancement of neointima organization,
Figure 1. Study design.
doi:10.1371/journal.pone.0014314.g001
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treated animals, the inflammatory reaction observed was slight,
and consisted of some scattered mononuclear inflammatory cells,
mostly lymphocytes and macrophages (Figure 2E) and foreign
body giant cells (Figure 2F), distributed around or in the area of
the stent struts in LADs and peripheral arteries.
In conclusion, histological analysis of the stented vessels in this
double injury pig model showed (i) the stent implantation
generated no or very limited injury to the vessel wall; (ii) there
was a robust neointimal response in both LADs and peripheral
arteries, with typical features of the biological response of vascular
tissue to the stents; therefore providing a solid preclinical model to
study restenosis and observe subsequent pharmacological effects of
drug candidates.
Pharmacokinetics of ELN 457946
Plasma levels of ELN 457946 (a4 integrin inhibitor drug
candidate) and pharmacokinetic parameters were evaluated as part
of the restenosis study (4 weekly doses of 30 mg/kg). Area under the
plasma concentration-time profile and maximal plasma concentra-
tions increased over time, suggesting accumulation of ELN 457946
in the plasma with repeated weekly administration. By Week 4,
mean peak plasma concentration (Cmax) was 865 mg/mL and time
of maximal plasma concentration (Tmax) was 39.4 hours. Trough
Figure 2. Histological analysis of the stented vessels. Representative images of elastin trichrome (A) and hematoxylin and eosin (B–F) stainings
of sections in stented arteries. (A) Neointima injury (score 0). Arrows indicate intact elastic lamina in the carotid from a vehicle-treated animal. (B)
Complete endothelialization in the LAD from a vehicle-treated animal. Arrows indicate endothelial cells. (C) Full thickness neointima with well-
organized smooth muscle cells, in the RI artery from a vehicle-treated animal. (D) Neointima fibrin (score 1), as typically observed around the stent
struts, in the LAD from a vehicle-treated animal. Asterisks in Panels C, E and F indicate areas of fibrin deposits. (E, F): Inflammation in the distal region
of a right iliac artery from a vehicle-treated animal. (E) Arrowheads/long arrows/short arrows, indicate eosinophils, lymphocytes and macrophages,
respectively. (F): Arrow indicates a foreign body giant cell. Bar=100 mm.
doi:10.1371/journal.pone.0014314.g002
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dose on Weeks 2, 3 and 4 suggested that steady-state levels had not
yet been reached by Week 4 (concentration: 464 mg/mL), and were
consistent with the slow elimination of this compound. In
conclusion, all ELN 457946-treated animals were exposed to
continuous systemic levels of ELN 457946 throughout the study,
starting approximately 24 hours after the first dose until euthanasia,
one month after treatment start.
Effects of ELN 457946 on clinical pathology and
inflammation
Hematology parameters, including white blood cells differential
counts, were measured over the course of the study. All red blood
cell parameters and eosinophil, basophil and reticulocyte counts
were similar in ELN 457946- compared to vehicle-treated animals
throughout the study (data not shown). Prior to the first ELN
457946 dose (Day -1, baseline), whole counts of white blood cells
(WBC), lymphocytes and monocytes were similar in ELN 457946-
and vehicle-treated animals (Figure 3). Starting 48 hours after the
second dose (Day 9) and during the remainder of the study, mean
WBC counts as well as lymphocyte and monocyte counts were
consistently higher in ELN 457946-treated animals compared to
vehicle-treated animals (Figure 3). Lymphocyte counts in ELN
457946-treated animals were also significantly increased compared
to baseline lymphocyte counts. These changes in WBC, lympho-
cyte, and monocyte counts were consistent with the pharmaco-
logical activity of ELN 457946 and demonstrated that ELN
457946 was present and pharmacologically active in the blood
circulation of ELN 457946-treated animals.
Effects of ELN 457946 on inflammation were further
investigated by qualitative and semi-quantitative histological
analysis. While the overall inflammatory reaction was mild in
LAD (average score of 0.3360.56) and peripheral arteries (average
score of 0.2860.33 in carotid, and 0.7860.66 in iliac arteries)
from vehicle-treated animals (Figure 2E–F, and Figure 4A), there
was virtually no inflammation in LAD and peripheral arteries
from ELN 457946-treated animals (average score of 0.0060.00 in
LAD and carotid, and 0.0760.15 in iliac arteries; Figure 4B).
Vessel wall injury, a potent factor influencing inflammatory
response to stents was low and comparable in control and treated
groups. Therefore, treatment with ELN 457946 strikingly
decreased the severity of the inflammatory reaction at the stent
site in this double injury pig model.
In conclusion, four weekly treatments with 30 mg/kg ELN
457946 caused increased lymphocytes counts in the blood
circulation (from decreased lymphocyte trafficking into inflamma-
tory sites), and decreased inflammatory reaction to endothelial cell
denudation and stent implantation at the stent sites in LAD and in
peripheral arteries.
Effects of ELN 457946 on restenosis
We then investigated potential pharmacological effects of ELN
457946 on restenosis in LAD and peripheral arteries. This double
injury model produced average levels of restenosis around 60% in
LAD, 30% in the iliac and ,15% in the carotid arteries. The lack
or very limited amount of procedural injury to the vessel wall
allowed valid quantitative morphometry analyses for all stented
vessels and comparison between treatment groups. For LAD, the
average injury was slightly lower in the ELN 457946-treated group
(score: 0.3360.52) than in the vehicle-treated group (score:
0.5060.66). However, the difference was small, within normal
variability, and negligible with respect to the magnitude of the
corresponding neointimal response. For peripheral vessels, the
average injury was very low, and equivalent in the ELN 457946
and vehicle-treated groups (average scores between 0.0060.00 in
the carotid and 0.0660.14 in the iliac).
Figure 4 shows vessel lumen and the extent of restenosis typically
observed in carotid, iliac and LAD arteries (Figure 4C–D, E–F, and
G–H, respectively). Quantitative morphometric measurements are
summarized in Table 1. Peripheral (iliac and carotid) arteries from
ELN 457946 and vehicle-treated animals exhibited similar average
vessel size. After treatment with ELN 457946, neointima area and
thickness were significantly decreased in carotid arteries and lumen
area was significantly increased in iliac arteries. This resulted in
approximately 33% and 29% statistically significant decreases in
average percent stenosis in carotid and iliac arteries, respectively,
following treatment with ELN 457946. Prenecropsy quantitative
angiograms revealed changes in the arterial lumen sizes consistent
with these findings (data not shown).
Figure 3. Effects of ELN 457946 on hematology parameters.
Whole blood counts of white blood cells (WBC; top panel), lymphocytes
(middle panel) and monocytes (bottom panel), over time after dosing
with vehicle (black triangles) or ELN 457946 (grey squares). Dose
administrations were done at weekly intervals (black arrows). Blood was
collected prior to dose (predose or trough levels), 24 hours after the
initial dose, and/or 48 hours post-dose, and prior to necropsy. * p,0.05
and ** p,0.01, when compared to vehicle group using Mann-Whitney.
# p,0.05, when compared to baseline data (Day -1) using Mann-
Whitney.
doi:10.1371/journal.pone.0014314.g003
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slightly increased average vessel size compared to vehicle-treated
animals (increased artery area; Table 1). Neointima area and
thickness appeared slightly decreased and lumen area slightly
increased, resulting in an approximately 12% decrease in average
percent stenosis after treatment with ELN 457946. However, this
decrease did not reach statistical significance. Since the magnitude
of the decrease in stenosis was smaller in LAD than in peripheral
arteries, and because of the slightly lower level of procedural injury
observed in LAD arteries from ELN 457946-treated compared to
vehicle-treated animals, the effects of ELN 457946 on stenosis in
coronary arteries are less clear. However, the consistency of the
Figure 4. Effects of ELN 457946 on inflammation and restenosis. Representative hematoxylin and eosin (A, B) and elastin trichrome (C–H)
stainings from vehicle- treated (left) and ELN 457946-treated (right) animals. (A, B): Inflammation in proximal region of stented left carotid artery.
Arrows indicate inflammatory cells localized around the stent struts in vehicle-treated animal, absent in ELN 457946 animal. Bar=200 mm. (C–H):
Restenosis in stented left carotid (C, D), right iliac (E, F), and LAD (G, H) arteries. Bar=1 mm.
doi:10.1371/journal.pone.0014314.g004
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reduced inflammatory reaction, suggested the observed 12%
decrease in LAD stenosis is related to treatment with ELN 457946.
Discussion
In this study, we combined endothelial denudation by balloon
angioplasty and bare metal stent placement in pigs, and
characterized this new double injury model. A consistent low
level of procedural injury was obtained, allowing valid comparison
of the restenotic response between animals, a critical prerequisite
for subsequent assessments. Complete healing was observed as
evidenced by full or nearly full endothelialization, lack of
substantial amounts of residual fibrin and complete maturation
of the neointima into a stable fibromuscular layer covering all
struts. The double injury procedure lead to a robust neointimal
response in coronary arteries (average levels of restenosis around
60%), as well as in highly elastic, compliant- and stretch-resistant
peripheral arteries (average levels of restenosis of 30% in the iliac
and ,15% in the carotid arteries). With the exception of the
carotid arteries, these restenosis percentages correspond to a
robust response, superior to what is typically observed one month
after stenting alone in pigs. For example, percentage area stenoses
of 42% (stent implantation only [9]), and 55% (stent implantation
combined with a 13-week hypercholesterolemic diet and early
endothelial abrasion [9]; or severe arterial injury with stents
delivered on oversized angioplasty balloons [21]) were reported for
porcine coronary arteries. In one previous report, combination of
balloon injury using an oversized balloon and implantation of
biliary stents led to a 44% area stenosis in swine femoral arteries,
allowing to show significant differences in stenosis after intravas-
cular sonotherapy [22]. In the context of preclinical efficacy
studies, our double injury pig model appears particularly relevant
to assess pharmacological effects of drug candidates on restenosis,
including for peripheral arteries assessment. Future studies to
evaluate and quantify effects of clinically efficacious drugs with
different mechanisms of action, (e.g. rapamycin [12,23] or tranilast
[24,25]) in this model may prove useful to further validate the
model for coronary restenosis and to identify positive controls for
preclinical assessments of new pharmacological agents. A number
of different candidate drugs with various modes of action (for
reviews, see [26,27]), including anti-proliferative (e.g. cytarabine,
doxorubicin, vincristine, colchicines, sirolimus), and anti-inflam-
matory agents (e.g. bisphosphonates, like clodronate, pamidronate,
alendronate, ISA-13-1 [28,29]); genes, growth factors and
cytokines (e.g. PDGF receptor kinase inhibitors [30], or extracel-
lular matrix metalloprotease MMP-9 [12]); lipids (e.g. ceramide
[31]); and anti-platelet drugs (e.g. cilostazol [32]) are currently
under investigation for the treatment of restenosis and could be
tested in this double injury model.
Using this animal model, we tested an a4 integrin inhibitor,
ELN 457946, and could demonstrate an important role for a4
integrin inhibition in the response to arterial injury. Pharmaco-
logical levels of ELN 457946 were achieved and maintained over
the course of the study, with inflammatory cell infiltration in LAD
and peripheral arteries fully inhibited. A small reduction (,12%)
in area percent stenosis was observed in LAD arteries, and was
associated with reduced inflammatory response. This decrease did
not reach statistical significance but was consistent with effects on
other morphometric measurements, suggesting this decrease in
LAD neointimal response was the result of treatment with ELN
457946. There was a statistically significant decrease (,30%) in
area percent stenosis in treated peripheral arteries when compared
to the controls, with a clear relationship to ELN 457946 treatment.
The response to ELN 457946 treatment appeared quantitatively
more important in peripheral arteries than in coronary arteries.
This might be explained in part by the more important restenosis
response, classically observed in the coronary arteries compared to
more elastic peripheral vessels [33]. This apparent difference was
not considered to reflect a different response to treatment, since all
vessels (LAD, carotid and iliac) exhibited qualitatively similar
healing and inflammation characteristics after treatment with ELN
457946.
Further refinement of the dosing scheme of ELN 457946 and of
timing in relation with stent placement (e.g. second dose
administered 1 week before stent placement, to achieve higher
blood levels of ELN 457946 before surgery) might allow to observe
more significant differences in the coronary restenosis response.
Our results are particularly interesting in light of recent
controversies over safety concerns with the use of drug-eluting
stents (DES). Drug-eluting stents (DES) have shown remarkable
effectiveness in reducing neointima formation and in-stent
restenosis [8]. However, incidences of acute, subacute or late
thrombosis events have been reported recently with use of DES,
due to incomplete healing (absent endothelialization, increased
level of inflammation and unresorbed fibrin deposits) [4].
Recently, comparison of clinical outcomes in patients treated with
either bare metal stents or drug-eluting stents has revealed similar
1- year mortality, myocardial infarction, and a trend toward
increased target-vessel revascularization in DES vs bare metal
stented arteries [34,35]. In addition, chronic inflammatory
reactions to polymer coating and the potential for hypersensitivity
reactions is also a long term concern for current drug eluting stents
[36,37]. These findings have deeply renewed the interest of the
scientific and medical communities, for alternative or comple-
Table 1. Summary of histomorphometric measurements.
Artery Treatment
Artery area
(mm
2)
Neointima area
(mm
2)
Lumen area
(mm
2)
Neointima
thickness (mm)
Area stenosis
(%)
LAD vehicle
ELN 457946
7.6861.45
8.2761.45
4.1060.59
3.9160.94
2.5161.36
3.1661.38
5816127
5146141
63.7612.7
56.5614.4
iliac vehicle
ELN 457946
29.6562.15
30.3960.95
7.5162.78
5.4860.64
18.6262.89
21.4061.16 {
4566183
318643
28.8610.2
20.562.8 *
carotid vehicle
ELN 457946
28.0061.44
27.7162.07
3.7260.59
2.4960.60 *
19.0061.54
20.2161.29
231643
153639 *
16.463.2
11.062.8 {
Data are means 6 SD;
{P#0.05;
*P#0.01.
doi:10.1371/journal.pone.0014314.t001
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PLoS ONE | www.plosone.org 7 December 2010 | Volume 5 | Issue 12 | e14314mentary interventions to reduce restenosis, including systemic
pharmacological treatments in conjunction with bare metal or
drug eluting stent placement. Based on our results, ELN 457946
represents a promising therapeutic approach in this context, and
further investigation should determine the clinical relevance of the
effects observed in this new pig model.
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